Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Tilray Brands seeks US$250M for U.S. cannabis expansion

 Trevor Abes Trevor Abes , The Market Online
0 Comments| May 17, 2024

{{labelSign}}  Favorites
{{errorMessage}}

  • Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million through an at-the-market equity program to fund its U.S. expansion plan
  • The move intends to capitalize on the pending U.S. reclassification of cannabis as a lower-risk drug
  • Tilray is a global cannabis and consumer packaged goods company managing more than 20 brands in more than 20 countries
  • Tilray stock has given back 10.77 per cent year-over-year and 85.24 per cent over the past five years

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million through an at-the-market equity program to fund its U.S. expansion plan.

It intends to use the funds for investments or acquisitions to unlock value from regulatory advancements or other prospective expansion opportunities.

TD Securities and Jefferies are acting as distributors, allowing them to sell TLRY stock according to timing, quantity and valuation factors determined by Tilray management.

Investors can consult the prospectus supplement for the offering filed with the U.S. Securities and Exchange Commission.

Why is Tilray tapping the public market?

The capital raise follows cannabis’ proposed reclassification from a Schedule I controlled substance, a category that includes heroin and ecstasy, to a Schedule III substance, which include ketamine, Tylenol with codeine, and other compounds with accepted medical benefits.

U.S. President Joe Biden has voiced his support for the legislative change, stating in a video posted Thursday on X that it will help to reverse “long-standing inequities” and “lift barriers to housing, employment, small business loans and so much more for tens of thousands of Americans.”

The proposal is now under a 60-day period for public comment, after which the U.S. Drug Enforcement Administration is expected to officially reschedule the drug, marking the federal government’s first acknowledgement of cannabis’ medical benefits, allowing federal researchers to study it for the first time since the Controlled Substances Act passed in 1971, and unlocking tens of billions in value in a market expected to grow steadily over the next five years.

About Tilray Brands

Tilray is a global cannabis and consumer packaged goods company managing more than 20 brands in more than 20 countries, including Broken Coast, Redecan and Good Supply.

Tilray stock (TSX:TLRY) last traded at C$2.90 per share. The stock has given back 10.77 per cent year-over-year and 85.24 per cent over the past five years.

Join the discussion: Find out what everybody’s saying about this cannabis stock on the Tilray Brands Inc. Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.



Tags:

{{labelSign}}  Favorites
{{errorMessage}}


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company